

Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease-related lung fibrosis

Veronika K. Jaeger¹, Dirk Lebrecht^{2,3}, Andrew G. Nicholson^{4,5}, Athol Wells^{5,6}, Harshil Bhayani⁷, Amiq Gazdhar⁸, Michael Tamm⁹, Nils Venhoff², Thomas Geiser⁸, and Ulrich A. Walker^{1*}

¹ Department of Rheumatology, University Hospital Basel, Basel, Switzerland

² Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

³ Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁴ Department of Histopathology, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust; London, UK

⁵ National Heart and Lung Institute, Imperial College, London, UK

⁶ Interstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK

⁷ Royal Brompton and Harefield NHS Foundation Trust; London, UK

⁸ Department of Pulmonary Medicine, University Hospital Bern, Bern Switzerland

⁹ Department of Pneumology, University Hospital Basel, Basel, Switzerland

Supplementary figure 1: Representative image of an agarose gel detecting the common mtDNA deletion. Lane 1: 100bp DNA ladder as a size marker (Sigma). Lane 2: Negative control plasmid without mtDNA insert. Lane 3: Healthy control DNA. Lanes 4-6: Detection of common deletions in DNA from patients with interstitial lung disease in different lung areas (lower lobe, upper lobe, and upper lobe, respectively). Lane 7: Positive control (plasmid containing the common mtDNA deletion).

